| Literature DB >> 32470572 |
Joaquim Radua1, Eduard Vieta2, Russell Shinohara3, Peter Kochunov4, Yann Quidé5, Melissa J Green5, Cynthia S Weickert6, Thomas Weickert5, Jason Bruggemann7, Tilo Kircher8, Igor Nenadić8, Murray J Cairns9, Marc Seal10, Ulrich Schall9, Frans Henskens11, Janice M Fullerton12, Bryan Mowry13, Christos Pantelis14, Rhoshel Lenroot15, Vanessa Cropley16, Carmel Loughland17, Rodney Scott17, Daniel Wolf18, Theodore D Satterthwaite18, Yunlong Tan19, Kang Sim20, Fabrizio Piras21, Gianfranco Spalletta22, Nerisa Banaj21, Edith Pomarol-Clotet23, Aleix Solanes24, Anton Albajes-Eizagirre25, Erick J Canales-Rodríguez26, Salvador Sarro27, Annabella Di Giorgio28, Alessandro Bertolino29, Michael Stäblein30, Viola Oertel30, Christian Knöchel30, Stefan Borgwardt31, Stefan du Plessis32, Je-Yeon Yun33, Jun Soo Kwon34, Udo Dannlowski35, Tim Hahn35, Dominik Grotegerd35, Clara Alloza36, Celso Arango37, Joost Janssen36, Covadonga Díaz-Caneja37, Wenhao Jiang38, Vince Calhoun39, Stefan Ehrlich40, Kun Yang41, Nicola G Cascella41, Yoichiro Takayanagi42, Akira Sawa43, Alexander Tomyshev44, Irina Lebedeva44, Vasily Kaleda44, Matthias Kirschner45, Cyril Hoschl46, David Tomecek47, Antonin Skoch48, Therese van Amelsvoort49, Geor Bakker49, Anthony James50, Adrian Preda51, Andrea Weideman51, Dan J Stein52, Fleur Howells53, Anne Uhlmann54, Henk Temmingh55, Carlos López-Jaramillo56, Ana Díaz-Zuluaga57, Lydia Fortea58, Eloy Martinez-Heras59, Elisabeth Solana59, Sara Llufriu59, Neda Jahanshad60, Paul Thompson61, Jessica Turner38, Theo van Erp62.
Abstract
A common limitation of neuroimaging studies is their small sample sizes. To overcome this hurdle, the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium combines neuroimaging data from many institutions worldwide. However, this introduces heterogeneity due to different scanning devices and sequences. ENIGMA projects commonly address this heterogeneity with random-effects meta-analysis or mixed-effects mega-analysis. Here we tested whether the batch adjustment method, ComBat, can further reduce site-related heterogeneity and thus increase statistical power. We conducted random-effects meta-analyses, mixed-effects mega-analyses and ComBat mega-analyses to compare cortical thickness, surface area and subcortical volumes between 2897 individuals with a diagnosis of schizophrenia and 3141 healthy controls from 33 sites. Specifically, we compared the imaging data between individuals with schizophrenia and healthy controls, covarying for age and sex. The use of ComBat substantially increased the statistical significance of the findings as compared to random-effects meta-analyses. The findings were more similar when comparing ComBat with mixed-effects mega-analysis, although ComBat still slightly increased the statistical significance. ComBat also showed increased statistical power when we repeated the analyses with fewer sites. Results were nearly identical when we applied the ComBat harmonization separately for cortical thickness, cortical surface area and subcortical volumes. Therefore, we recommend applying the ComBat function to attenuate potential effects of site in ENIGMA projects and other multi-site structural imaging work. We provide easy-to-use functions in R that work even if imaging data are partially missing in some brain regions, and they can be trained with one data set and then applied to another (a requirement for some analyses such as machine learning).Entities:
Keywords: Brain; Cortical thickness; Gray matter; Mega-analysis; Neuroimaging; Schizophrenia; Volume
Mesh:
Year: 2020 PMID: 32470572 PMCID: PMC7524039 DOI: 10.1016/j.neuroimage.2020.116956
Source DB: PubMed Journal: Neuroimage ISSN: 1053-8119 Impact factor: 6.556
Previous ENIGMA projects that included both mega-analyses and meta-analyses.
| RE-Meta | ME-Mega | |
|---|---|---|
| Subcortical volumes in obsessive-compulsive disorder ( | ↓ in1 ROI and t in ↑ ROI | ↓ in 1 ROI and ↑ in 1 ROI |
| Fractional anisotropy in bipolar disorder ( | ↓ in 23 out of 44 ROIs | ↓ in 29 out of 44 ROIs |
| Cortical thickness in obsessive-compulsive disorder ( | No findings | ↓ in 2 ROIs |
| Surface area in obsessive-compulsive disorder ( | ↓ in 1 ROI | ↓ in 1 ROI |
| Subcortical volumes in autism spectrum disorder ( | ↓ in 3 ROIs | ↓ in 4 ROIs |
| Cortical thickness in autism spectrum disorder ( | ↑ in 3 ROIs ↓I in 10 ROIs | ↑ in 9 ROIs and ↓ in 7 ROIs |
Footnote: ROI: region of interest. ME-Mega: mixed-effects mega-analysis; RE-Meta: random-effects meta-analysis.
Description of the overall sample.
| Sample size | Age (SD) | Females | Age of onset (SD) | Duration of illness (SD) | PANSS | SAPS (SD) | SANS (SD) | CDE (SD) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total (SD) | Positive (SD) | Negative (SD) | |||||||||
| Patients with schizophrenia | 2897 | 33.9 (12.0) | 34.2% | 22.8 (7.1) | 12.1 (12.5) | 60.5 (25.3) | 15.5 (6.8) | 16.6 (7.8) | 20.2 (18.5) | 23.0 (16.9) | 426 (591) |
| Healthy controls | 3141 | 33.3 (13.2) | 49.0% | ||||||||
Footnote: CDE: chlorpromazine dose equivalent; PANSS: Positive and Negative Syndrome Scale; SANS: Scale for the Assessment of Negative Symptoms; SAPS: Scale for the Assessment of Positive Symptoms; SD: standard deviation.
Fig. 1.Steps of each iteration of the permutation test used to compare the statistical significance between random-effects meta-analysis, mixed-effects mega-analysis and ComBat mega-analysis
Footnote: ComBat-Mega: ComBat mega-analysis; ME-Mega: mixed-effects mega-analysis; RE-Meta: random-effects meta-analysis.
Effect sizes and confidence intervals derived from the ComBat mega-analysis.
| Thickness | Surface area | ||
|---|---|---|---|
| Bankssts | L | −0.37 (−0.43,−0.32) | −0.2 (−0.25,−0.14) |
| R | −0.39 (−0.44,−0.33) | −0.2 (−0.26,−0.15) | |
| Caudal anterior cingulate | L | −0.12 (−0.18,−0.07) | −0.16 (−0.21,−0.11) |
| R | −0.15 (−0.2,−0.1) | −0.2 (−0.26,−0.15) | |
| Caudal middle frontal | L | −0.36 (−0.41,−0.3) | −0.18 (−0.23,−0.13) |
| R | −0.33 (−0.38,−0.27) | −0.18 (−0.23,−0.13) | |
| Cuneus | L | −0.15 (−0.21,−0.1) | −0.19 (−0.24,−0.13) |
| R | −0.19 (−0.24,−0.14) | −0.14 (−0.19,−0.09) | |
| Entorhinal | L | −0.11 (−0.17,−0.06) | −0.16 (−0.21,−0.1) |
| R | −0.07 (−0.12,−0.01) | −0.1 (−0.16,−0.05) | |
| Frontal pole | L | −0.19 (−0.24,−0.13) | −0.18 (−0.23,−0.13) |
| R | −0.2 (−0.25,−0.14) | −0.09 (−0.15,−0.04) | |
| Fusiform | L | −0.44 (−0.49,−0.38) | −0.22 (−0.27,−0.17) |
| R | −0.45 (−0.5,−0.39) | −0.26 (−0.32,−0.21) | |
| Inferior parietal | L | −0.41 (−0.47,−0.36) | −0.22 (−0.27,−0.16) |
| R | −0.38 (−0.43,−0.33) | −0.22 (−0.28,−0.17) | |
| Inferior temporal | L | −0.39 (−0.44,−0.33) | −0.25 (−0.31,−0.2) |
| R | −0.34 (−0.39,−0.29) | −0.22 (−0.27,−0.16) | |
| Insula | L | −0.37 (−0.43,−0.32) | −0.17 (−0.22,−0.11) |
| R | −0.37 (−0.42,−0.32) | −0.13 (−0.18,−0.07) | |
| Isthmus cingulate | L | −0.25 (−0.3,−0.2) | −0.06 (−0.12,−0.01) |
| R | −0.25 (−0.3,−0.2) | −0.09 (−0.14,−0.04) | |
| Lateral occipital | L | −0.27 (−0.33,−0.22) | −0.19 (−0.24,−0.13) |
| R | −0.29 (−0.35,−0.24) | −0.18 (−0.24,−0.13) | |
| Lateral orbitofrontal | L | −0.3 (−0.35,−0.24) | −0.2 (−0.25,−0.14) |
| R | −0.34 (−0.39,−0.29) | −0.19 (−0.24,−0.14) | |
| Lingual | L | −0.3 (−0.35,−0.24) | −0.21 (−0.26,−0.16) |
| R | −0.32 (−0.37,−0.27) | −0.18 (−0.23,−0.13) | |
| Medial orbitofrontal | L | −0.2 (−0.25,−0.14) | −0.19 (−0.25,−0.14) |
| R | −0.25 (−0.31,−0.2) | −0.19 (−0.25,−0.14) | |
| Middle temporal | L | −0.38 (−0.44,−0.33) | −0.24 (−0.3,−0.19) |
| R | −0.36 (−0.41,−0.3) | −0.26 (−0.31,−0.2) | |
| Paracentral | L | −0.33 (−0.38,−0.27) | −0.11 (−0.17,−0.06) |
| R | −0.31 (−0.37,−0.26) | −0.12 (−0.18,−0.07) | |
| Parahippocampal | L | −0.21 (−0.26,−0.15) | −0.12 (−0.17,−0.06) |
| R | −0.21 (−0.26,−0.16) | −0.19 (−0.25,−0.14) | |
| Pars opercularis | L | −0.36 (−0.42,−0.31) | −0.18 (−0.23,−0.13) |
| R | −0.38 (−0.44,−0.33) | −0.2 (−0.26,−0.15) | |
| Pars orbitalis | L | −0.31 (−0.36,−0.26) | −0.21 (−0.26,−0.15) |
| R | −0.3 (−0.35,−0.25) | −0.17 (−0.23,−0.12) | |
| Pars triangularis | L | −0.29 (−0.34,−0.23) | −0.18 (−0.23,−0.12) |
| R | −0.36 (−0.41,−0.3) | −0.16 (−0.22,−0.11) | |
| Pericalcarine | L | 0 (−0.06,0.05) | −0.14 (−0.19,−0.08) |
| R | −0.06 (−0.11,0) | −0.09 (−0.15,−0.04) | |
| Postcentral | L | −0.3 (−0.36,−0.25) | −0.24 (−0.29,−0.19) |
| R | −0.28 (−0.33,−0.23) | −0.22 (−0.27,−0.16) | |
| Posterior cingulate | L | −0.24 (−0.3,−0.19) | −0.13 (−0.19,−0.08) |
| R | −0.28 (−0.34,−0.23) | −0.18 (−0.23,−0.13) | |
| Precentral | L | −0.38 (−0.43,−0.32) | −0.19 (−0.24,−0.14) |
| R | −0.38 (−0.43,−0.32) | −0.2 (−0.26,−0.15) | |
| Precuneus | L | −0.31 (−0.36,−0.25) | −0.17 (−0.23,−0.12) |
| R | −0.34 (−0.4,−0.29) | −0.17 (−0.22,−0.11) | |
| Rostral anterior cingulate | L | −0.11 (−0.17,−0.06) | −0.17 (−0.22,−0.12) |
| R | −0.13 (−0.18,−0.08) | −0.18 (−0.24,−0.13) | |
| Rostral middle frontal | L | −0.26 (−0.32,−0.21) | −0.24 (−0.29,−0.18) |
| R | −0.3 (−0.35,−0.24) | −0.21 (−0.26,−0.16) | |
| Superior frontal | L | −0.33 (−0.38,−0.28) | −0.24 (−0.3,−0.19) |
| R | −0.35 (−0.41,−0.3) | −0.24 (−0.29,−0.18) | |
| Superior parietal | L | −0.28 (−0.33,−0.23) | −0.2 (−0.25,−0.14) |
| R | −0.29 (−0.35,−0.24) | −0.22 (−0.27,−0.17) | |
| Superior temporal | L | −0.36 (−0.41,−0.3) | −0.22 (−0.27,−0.17) |
| R | −0.38 (−0.43,−0.32) | −0.23 (−0.29,−0.18) | |
| Supramarginal | L | −0.42 (−0.47,−0.36) | −0.17 (−0.23,−0.12) |
| R | −0.39 (−0.44,−0.34) | −0.19 (−0.25,−0.14) | |
| Temporal pole | L | −0.17 (−0.22,−0.12) | −0.09 (−0.14,−0.03) |
| R | −0.17 (−0.22,−0.11) | −0.07 (−0.12,−0.01) | |
| Transverse temporal | L | −0.26 (−0.31,−0.2) | −0.15 (−0.21,−0.1) |
| R | −0.29 (−0.34,−0.23) | −0.19 (−0.24,−0.14) | |
| Volume | |||
| Accumbens | L | −0.06 (−0.11,−0.01) | |
| R | −0.14 (−0.19,−0.09) | ||
| Amygdala | L | −0.25 (−0.3,−0.2) | |
| R | −0.24 (−0.3,−0.19) | ||
| Caudate | L | 0.03 (−0.03,0.08) | |
| R | 0.03 (−0.02,0.08) | ||
| Hippocampus | L | −0.43 (−0.48,−0.38) | |
| R | −0.42 (−0.48,−0.37) | ||
| Lateral Ventricle | L | 0.25 (0.19,0.3) | |
| R | 0.2 (0.15,0.26) | ||
| Pallidum | L | 0.28 (0.23,0.33) | |
| R | 0.19 (0.14,0.24) | ||
| Putamen | L | 0.09 (0.04,0.15) | |
| R | 0.1 (0.05,0.15) | ||
| Thalamus | L | −0.33 (−0.39,−0.28) | |
| R | −0.35 (−0.4,−0.29) | ||
Fig. 2.Forest plot for random-effect meta-analysis (light red), mixed-effects mega-analysis (blue) and ComBat mega-analysis (dark green).
Footnote: The width of the confidence intervals in the legend corresponds to the mean width of the confidence intervals across the brain. ComBat-Mega: ComBat mega-analysis; ME-Mega: mixed-effects mega-analysis; RE-Meta: random-effects meta-analysis.
Fig. 3.Hedges’ g and p-values of random-effect meta-analysis, mixed-effects mega-analysis and ComBat mega-analysis in the comparison of ENIGMA brain data between 2897 patients with schizophrenia and 3141 healthy controls.
Footnote: Each cross represents an ROI. ComBat-Mega: ComBat mega-analysis; ME-Mega: mixed-effects mega-analysis; RE-Meta: random-effects meta-analysis. The top plots show that ComBat-Mega effect sizes are similar to RE-Meta and ME-Mega effect sizes, as crosses are mostly distributed around the diagonal lines. The bottom plots show that ComBat-Mega p-values are substantially smaller than RE-Meta p-values (crosses are clearly above the diagonal line), and slightly smaller than ME-Mega p-values (crosses tend to be slightly above the diagonal line).
Fig. 4.Median difference between logit-transformed p-values derived from ComBat mega-analysis and logit-transformed p-values derived from random-effects meta-analysis and mixed-effects mega-analysis in the original data (red) and in the permuted data (histograms).
Footnote: ComBat-Mega: ComBat mega-analysis; ME-Mega: mixed-effects mega-analysis; RE-Meta: random-effects meta-analysis. The histograms (in gray) show the expected ComBat-Mega-related increase of statistical significance by chance, and the arrows (in red) show the actual increase. The latter is clearly larger than that former (negative values mean that ComBat-Mega increases statistical significance).
Fig. 5.Relationship between the intra-site variance/total variance ratio and ComBat mega-analysis-related increase of statistical significance.
Footnote: ComBat-Mega: ComBat mega-analysis; ME-Mega: mixed-effects mega-analysis; RE-Meta: random-effects meta-analysis. The ComBat-Mega-related increase of statistical significance (negative values in the Y axis) is larger in regions with lower intra-site variance/variance ratio (around 50–70%).